Omnicell Reports Q4 GAAP Net Loss, Declining FY25 Profitability Amidst Modest Revenue Growth and New Product Launch

summarizeSummary

Omnicell reported a GAAP net loss for Q4 2025 and a significant drop in full-year GAAP net income, despite modest revenue growth and increased Annual Recurring Revenue. The company also provided modest guidance for 2026.

check_boxKey Events

• Q4 2025 Financial Performance

  Omnicell reported total revenues of $314 million, a 2% increase year-over-year. However, the company posted a GAAP net loss of $2 million (-$0.05 per diluted share), a significant decline from GAAP net income of $16 million ($0.34 per diluted share) in Q4 2024. Non-GAAP net income also decreased to $18 million ($0.40 per diluted share) from $28 million ($0.60 per diluted share) in the prior year.

• Full Year 2025 Financial Performance

  For the full year 2025, total revenues grew 7% to $1.185 billion. GAAP net income fell substantially to $2 million ($0.04 per diluted share) from $13 million ($0.27 per diluted share) in 2024. Non-GAAP net income was $75 million ($1.62 per diluted share), down from $79 million ($1.71 per diluted share) in 2024.

• Product Bookings and Annual Recurring Revenue (ARR)

  Product bookings for the full year 2025 decreased by 4% to $535 million, attributed to the late stage of the XT upgrade cycle. Conversely, Annual Recurring Revenue (ARR) increased to $635.555 million as of December 31, 2025, up from $580.025 million in 2024.

• 2026 Financial Guidance

  The company provided full-year 2026 guidance, projecting total revenues between $1.215 billion and $1.255 billion, non-GAAP EBITDA between $145 million and $160 million, and non-GAAP EPS between $1.65 and $1.85. This guidance suggests modest growth compared to 2025 results.

auto_awesomeAnalysis

Omnicell's latest earnings report reveals a challenging fourth quarter with a GAAP net loss, a significant decline from the prior year's profit. Full-year GAAP net income also saw a substantial reduction. While the company achieved modest revenue growth for both the quarter and the full year, and saw an increase in Annual Recurring Revenue (ARR), the decline in product bookings and overall profitability raises concerns about operational efficiency and market demand for its core products. The introduction of the Titan XT dispensing system and positive industry recognition are strategic positives, but investors will be closely watching if these initiatives can translate into improved financial performance and a return to stronger profitability in 2026, as reflected in the modest guidance provided.